National Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangsu Kanion Pharmaceutical Co., Ltd.
Nanjing University of Chinese Medicine.
Biol Pharm Bull. 2024 May 18;47(5):978-987. doi: 10.1248/bpb.b23-00903. Epub 2024 Apr 18.
Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis and evidence of hepatocyte injury (ballooning) and inflammation, with or without liver fibrosis. In this study, after 12 weeks of induction, the mice were treated with emodin succinyl ethyl ester (ESEE) for four weeks at doses of 10/30/90 mg/kg/d. The blood analysis of experimental endpoints showed that ESEE exhibited significant therapeutic effects on the progression of disorders of glycolipid metabolism and the induced liver injury in the model animals. Histopathological diagnosis of the liver and total triglyceride measurements revealed that ESEE had a significant therapeutic effect on the histopathological features of nonalcoholic fatty liver disease/hepatitis, such as cellular steatosis and activation of intrahepatic inflammation. Additionally, ESEE was able to improve hepatocyte fat deposition, steatosis, and the course of intrahepatic inflammatory activity. Furthermore, it showed some inhibitory effect on liver fibrosis in the model animals. In summary, this study confirms the therapeutic effects of ESEE on the NAFLD/NASH model in C57BL/6J mice induced by a high-fat, high cholesterol, and fructose diet. These effects were observed through improvements in liver function, inhibition of fibrosis, and inflammatory responses. Changes in blood glucose levels, blood lipid metabolism, liver histopathological staining, liver fibrosis staining, and related pathological scores further supported the therapeutic effects of ESEE. Therefore, this study has important implications for the exploration of novel drugs for nonalcoholic fatty liver disease.
非酒精性脂肪性肝炎(NASH)是一种非酒精性脂肪性肝病(NAFLD)的亚型,其特征为肝脂肪变性和肝细胞损伤(气球样变)和炎症的证据,伴有或不伴有肝纤维化。在这项研究中,经过 12 周的诱导后,用大黄素琥珀酸乙酯(ESEE)对小鼠进行了四周的治疗,剂量分别为 10/30/90mg/kg/d。实验终点的血液分析表明,ESEE 对模型动物糖脂代谢紊乱和诱导的肝损伤的进展具有显著的治疗作用。肝脏的组织病理学诊断和总甘油三酯测量表明,ESEE 对非酒精性脂肪性肝病/肝炎的组织病理学特征具有显著的治疗作用,如细胞脂肪变性和肝内炎症的激活。此外,ESEE 能够改善肝细胞脂肪沉积、脂肪变性和肝内炎症活动的进程。此外,它对模型动物的肝纤维化有一定的抑制作用。总之,本研究证实了 ESEE 对高脂肪、高胆固醇和果糖饮食诱导的 C57BL/6J 小鼠非酒精性脂肪性肝病/脂肪性肝炎模型的治疗作用。这些作用通过改善肝功能、抑制纤维化和炎症反应来实现。血糖水平、血脂代谢、肝脏组织病理学染色、肝纤维化染色和相关病理评分的变化进一步支持了 ESEE 的治疗作用。因此,本研究对探索非酒精性脂肪性肝病的新型药物具有重要意义。